ArQule (ARQL) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.07 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.01. Analysts had a consensus of $-0.08. The company posted revenue of $1.07 million in the period, compared to analysts expectations of $1.10 million. The company’s revenue was down -64.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.
ArQule closed down -0.02 points or -1.19% at $1.66 with 54,219 shares getting traded on Tusday. Post opening the session at $1.68, the shares hit an intraday low of $1.6345 and an intraday high of $1.6988 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Dec 18, 2015, Michael D Loberg (director) purchased 3,719 shares at $2.16 per share price. According to the SEC, on Dec 16, 2015, Paolo Pucci (CEO) purchased 1,283 shares at $2.16 per share price. On Dec 14, 2015, Patrick J Zenner (director) purchased 2,300 shares at $2.15 per share price, according to the Form-4 filing with the securities and exchange commission.
ArQule Inc. is a clinical-stage biotechnology company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs target biological pathways implicated in a range of cancers and certain non-oncology indications. Its product candidates and programs are based on biological processes that lead to the proliferation and metastasis of cancer cells combined with generating product candidates possessing certain pre-selected drug-like properties. Its lead product candidate is tivantinib (ARQ 197) an orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company’s product candidates include ARQ 092 ARQ 087 ARQ 751 and ARQ 761.